Washington, DC–(ENEWSPF)–July 14, 2016. Regulators at the US Food and Drug Administration for the first time have approved the prescription of a liquid form of dronabinol (synthetic THC), to be marketed under the trade name Syndos.
The new drug formula, produced by Insys Therapeutics, is approved for use in patients with AIDS (as an appetite stimulant) and cancer (as an antiemetic).
The pharmaceutical provider is anticipated to publically launch the drug in the second half of this year.
The FDA initially approved the prescription use of dronabinol as an oral pill, marketed under the trade name Marinol, in 1985. Marinol is currently classified as a Schedule III controlled substance under the Controlled Substances Act. The prescription drug remains relatively unpopular with patients and physicians, largely because of its delayed onset, high degree